Intermittent Explosive Disorder Treatment: Evidence, Protocols, and the Limits of Current Practice
Oct 8, 2026
Intermittent explosive disorder (IED) is one of the few psychiatric conditions in which the first-line treatment is psychological, the pharmacological evidence is off-label, and no medication has received regulatory approval. The disorder affects 4% to 6% of the population and is characterized by recurrent, disproportionate outbursts of verbal or physical aggression that are impulsive rather than premeditated. The consequences are relational, occupational, and legal—and the treatment evidence, while growing, remains fragmented.
A 2025 comprehensive review and meta-analysis of 12 randomized controlled trials and 14 case studies provides the most current synthesis. Its central finding is both clarifying and sobering: psychological treatments, particularly cognitive behavioral therapy (CBT), showed significant effectiveness in reducing aggression and achieving full remission compared to pharmacological treatments. Fluoxetine demonstrated notable efficacy in managing irritability and achieving treatment response, but the pharmacological evidence base is thinner and less consistent.
This article examines the treatment landscape in detail: the assessment framework that should precede any intervention, the psychotherapy protocols with the strongest evidence, the pharmacological options and their limitations, the emerging vasopressin antagonist pipeline, and the practical principles that guide clinical decision-making when the evidence is incomplete.
Assessment and Diagnostic Framework
The DSM-5 Criteria and the Two Subtypes
The DSM-5 criteria for IED distinguish two patterns of aggressive behavior. A1 focuses on frequent verbal or non-injurious physical aggression occurring at least twice weekly over three months. A2 describes less frequent but more severe episodes, such as physical assaults causing injury or property damage, happening three times within a year.
Clinically, IED is also divided into two aggression subtypes. Instrumental aggression is goal-directed, does not primarily stem from anger, and involves some degree of prior planning. Hostile aggression (reactive aggression) results from anger, aims to injure a target, and involves little or no premeditation. The distinction matters for treatment: reactive aggression is more closely linked to the serotonergic and frontolimbic dysregulation that CBT and SSRIs target, while instrumental aggression may require different clinical attention.
Standardized Assessment
The Overt Aggression Scale Modified (OAS-M) is the most widely used measure for clinical trials targeting impulsive aggression and IED. It is a valid and reliable measure of state aggression with good psychometric properties, and it captures four subcomponents of aggressive acts. The OAS-M provides a quantifiable baseline and outcome measure that supports both treatment planning and documentation of medical necessity.
The Neurobiological Rationale for Treatment Targets
A 2025 systematic review of 24 studies on the etiology and neurobiology of IED found a multifactorial picture. The amygdala and orbitofrontal cortex play central roles in emotional regulation and impulse control. Altered serotonin function has been reported in individuals with IED. Childhood trauma, adverse family environments, and low socioeconomic status are significant predictors. These findings support interventions that target serotonergic signaling and the frontolimbic circuits involved in threat appraisal and response inhibition.
Psychotherapy — The First-Line Evidence
CBT: The Strongest Evidence for Full Remission
The 2025 meta-analysis found that CBT demonstrated significant effectiveness in reducing aggression and achieving full remission, and that individualized interventions like CBT and CRCST-I (Cognitive Relaxation and Coping Skills Training – Individual) showed significant improvements in full remission where group-based and pharmacological interventions did not. The authors conclude that these approaches “might better target the underlying cognitive and behavioural patterns contributing to IED”.
The clinical implication is that full remission is a realistic goal with individualized psychotherapy, and that group formats and medication alone are less likely to achieve it. The meta-analysis also found that follow-up time was a significant moderator of treatment efficacy, and that the psychological treatment trials with three-month follow-up data showed more consistent outcomes.
CBT for Adolescents: A 2026 Randomized Controlled Trial
A 2026 RCT of CBT for adolescents with IED (N = 42) provides some of the strongest recent evidence for this population. Participants received 12 weekly CBT sessions targeting maladaptive cognitions, emotion dysregulation, and self-control deficits. ANCOVA analyses showed significant group differences in overt aggression, hostile automatic thoughts, emotion dysregulation, impulse control, and global functioning. Compared with the wait-list group, adolescents receiving CBT demonstrated lower aggressive behavior, reduced hostile cognitions and hostile bias, fewer emotion regulation difficulties, and improved stop-signal reaction times (a behavioral measure of impulse control). Repeated-measures ANOVA confirmed that gains were maintained at three-month follow-up.
The authors conclude that “when CBT is delivered comprehensively in a multicomponent format targeting maladaptive cognitions, emotion dysregulation and self-control deficits, it can serve as an effective intervention for adolescents with IED”.
CRCST-I: The Structured Individual Protocol
Cognitive Relaxation and Coping Skills Training (CRCST) is a 12-session protocol that begins with relaxation training, followed by cognitive restructuring, then exposure therapy, and finally a focus on resisting aggressive impulses and preventive measures. The individualized version (CRCST-I) achieved significant full-remission improvements in the meta-analysis where the group version (CRCST-G) did not.
The CRCST structure is clinically useful because it sequences the components in a way that builds capacity progressively: the patient first learns physiological regulation (relaxation), then cognitive reappraisal (restructuring), then in-vivo practice (exposure), and finally relapse prevention. The individual format allows the therapist to tailor the exposure hierarchy and cognitive targets to the patient’s specific triggers and belief system.
Group CBT: Format and Evidence
Structured cognitive-behavioral group therapy has preliminary support. A program consisting of 15 weekly sessions plus three maintenance sessions, each lasting approximately 90 minutes, was described as “a promising approach to the treatment of IED” with a focus on anger management and cognitive coping. Group formats add social feedback, rehearsal under social stress, and normalization of the struggle, but the meta-analysis suggests they may be less likely to achieve full remission than individualized treatment.
DBT: Emotion Regulation and Distress Tolerance
DBT is increasingly cited as an effective approach for IED, particularly for patients with prominent emotion dysregulation and impulsivity. The four modules—mindfulness, distress tolerance, emotion regulation, and interpersonal effectiveness—map directly onto the deficits that maintain explosive outbursts. One key technique is “opposite action” : deliberately choosing a behavior that counters the angry impulse.
However, the evidence for DBT specifically in IED is less developed than for CBT. A 2025 case evaluation of a DBT-based protocol for impulse control and generalized anxiety found that the intervention “was not completely effective in managing anger, although it did achieve a reduction in anxiety symptoms”. DBT may be best positioned as an adjunct or as the primary modality for patients whose IED is embedded in broader emotion dysregulation, such as those with co-occurring borderline personality pathology.
Pharmacotherapy — Off-Label and Limited
Fluoxetine: The Most Studied Agent
Fluoxetine is the most extensively studied medication for IED. A double-blind, randomized, placebo-controlled trial (N = 100) used 20 to 60 mg per day, and it remains the reference study for SSRI efficacy in this population. Clinical guidance recommends titrating the dose every 1 to 2 weeks and continuing at the maximum tolerated dose for 8 to 12 weeks before concluding that the medication is ineffective.
The 2025 meta-analysis found that fluoxetine demonstrated notable efficacy in managing irritability and achieving treatment response, but not in achieving full remission. This is an important distinction: SSRIs may reduce the frequency and intensity of outbursts without resolving the underlying cognitive-behavioral patterns that CBT targets.
Mood Stabilizers: Mixed and Sometimes Counterproductive
Mood stabilizers, including carbamazepine, oxcarbazepine, and sodium valproate, are used off-label for severe aggression associated with IED. Case evidence suggests that carbamazepine may be considered as part of the treatment plan for severe aggression. However, the meta-analysis produced a striking finding: divalproex was the only pharmacological intervention associated with a significant increase in irritability scores. The authors call for further research to identify patient subgroups at risk for this adverse effect.
The clinical implication is that mood stabilizers should not be used reflexively. When they are used, irritability should be monitored systematically rather than assumed to improve.
The Emerging Pipeline: Vasopressin V1a Receptor Antagonists
The most significant pharmacological development in the IED pipeline is the class of highly selective, CNS-penetrant vasopressin V1a receptor antagonists. Phase 2 studies in both Huntington’s disease and IED have shown that these agents reduce aggressive behavior with an excellent safety profile, with efficacy signals across caregiver-reported, clinician-rated, and incident-based measures.
The lead compound, SRX246, met its primary endpoint in a Phase 2 trial in adults with IED, with results showing reductions in severe aggressive episodes and lessened disability due to the disorder. If approved, this would represent the first medication with a dedicated indication for pathological aggression and a mechanism of action distinct from serotonergic modulation. For clinicians, this is a pipeline to monitor rather than a current option, but it signals that the field is moving toward targeted treatment for aggression as a transdiagnostic dimension.
What the Meta-Analysis Says About Pharmacotherapy Overall
The 2025 meta-analysis found that pharmacological treatments had higher odds of treatment response compared to control, with fluoxetine showing a particularly strong effect. But full remission rates improved only with psychological interventions. This is the central pharmacological limitation: medication can reduce symptoms, but it does not appear to produce the comprehensive change that individualized psychotherapy achieves.
Combined and Multimodal Treatment
The Multimodal Consensus
The clinical literature consistently recommends a multimodal approach combining psychotherapy and pharmacotherapy. One overview states that IED treatment “is based on a multimodal approach, combining CBT with pharmacotherapy,” and that the pharmacological component includes SSRIs (e.g., fluoxetine) and mood stabilizers, supported by CBT. Another source describes the most effective treatment as “a combination of Cognitive Behavioral Therapy and selective serotonin reuptake inhibitors”.
The 2025 meta-analysis supports this position but refines it: psychological interventions are superior for full remission, while fluoxetine is useful for irritability and treatment response. The clinical logic is that medication can lower the intensity of the outbursts sufficiently for the patient to engage in the cognitive and behavioral work that produces lasting change.
Treating the Whole Person
A 2025 systematic review of IED etiology emphasizes that childhood trauma and adverse family environments contribute significantly to the disorder. This has treatment implications beyond symptom management: the therapist should assess for trauma history and consider trauma-informed approaches where indicated. The review also notes that genetic studies focusing on IED specifically are largely lacking, despite many studies examining aggression as a general trait.
Special Populations — Adolescents and Families
CBT for Adolescents: The 2026 Evidence
The 2026 RCT described above provides the strongest evidence for adolescent IED treatment. The multicomponent CBT format—targeting cognitions, emotion regulation, and impulse control—produced significant improvements that were maintained at three-month follow-up. The behavioral measure (stop-signal reaction time) is particularly notable because it demonstrates change at the level of impulse control, not just self-report.
Family Involvement
Young people with IED can benefit from family therapy to learn about the condition, parenting techniques, and communication styles that assist with symptom management. For adolescents, the family environment is often part of the maintaining cycle: explosive outbursts may be reinforced by family accommodation, or may be a response to family conflict. Family work addresses the systemic context that individual therapy may miss.
Group and Online Formats for Adolescents and Adults
Online group therapy and virtual intensive outpatient programs are increasingly available for IED, offering accessible formats for patients who cannot attend in-person treatment. The evidence for these formats is less robust than for individual CBT, but they expand access and may be appropriate for patients with mild to moderate presentations.
Practical Implementation and Documentation
Sequencing the Treatment
For a patient presenting with IED, a reasonable sequence is:
Comprehensive assessment, including the OAS-M to establish a baseline, trauma history, and differential diagnosis (substance use, bipolar disorder, intermittent explosive disorder vs. antisocial personality disorder, and medical causes of aggression).
Psychoeducation about the disorder, the aggression cycle, and the rationale for treatment.
Individual CBT or CRCST-I, typically 12 sessions, beginning with relaxation training and moving through cognitive restructuring, exposure, and relapse prevention.
Adjunctive pharmacotherapy with fluoxetine (20–60 mg/day) if irritability and outburst frequency are not sufficiently controlled, with titration every 1–2 weeks and an 8–12 week trial at the maximum tolerated dose.
Family or couples work where the relational context maintains the cycle.
Relapse prevention and follow-up, given the evidence that follow-up time moderates treatment efficacy.
Documentation That Supports Medical Necessity
Documentation should capture the frequency, intensity, and duration of outbursts (using OAS-M scores), the specific triggers, the functional impairment (relational, occupational, legal), the treatment targets (e.g., “hostile automatic thoughts,” “emotion dysregulation,” “impulse control”), and the modality and rationale (individual CBT, CRCST-I, fluoxetine, DBT). The documentation should avoid vague language like “anger issues” and instead describe the behavioral pattern in observable terms.
The Limits of the Evidence
The 2025 meta-analysis concludes that there is a significant lack of integrated treatment and calls for more robust evidence-based protocols and further research into the mechanisms of IED. The clinician working with IED must therefore practice with a degree of epistemic humility: the evidence supports CBT and fluoxetine, but the effect sizes are variable, the follow-up periods are short, and the field has not yet produced a definitive treatment protocol.
FAQ
What is the first-line treatment for intermittent explosive disorder?
Individual cognitive behavioral therapy (CBT) or Cognitive Relaxation and Coping Skills Training (CRCST-I) is the first-line treatment. The 2025 meta-analysis found that psychological treatments, particularly CBT, showed significant effectiveness in reducing aggression and achieving full remission compared to pharmacological treatments. Fluoxetine is the best-studied medication and is useful for irritability and treatment response, but it is not approved for IED and does not produce full remission on its own.
Is there an FDA-approved medication for IED?
No. There is no FDA-approved medication for intermittent explosive disorder. Fluoxetine, other SSRIs, and mood stabilizers are used off-label. The most promising pipeline development is the class of vasopressin V1a receptor antagonists, which have shown efficacy in Phase 2 trials for IED and Huntington’s disease aggression, but these are not yet clinically available.
How long does CBT for IED typically last?
The most studied protocols are 12 sessions. CRCST is a 12-session protocol that sequences relaxation training, cognitive restructuring, exposure, and relapse prevention. Group CBT programs have used 15 weekly sessions plus maintenance sessions. The 2026 adolescent RCT used 12 weekly CBT sessions and found gains maintained at three-month follow-up.
What is the difference between CBT and CRCST for IED?
CBT is the broader category. CRCST (Cognitive Relaxation and Coping Skills Training) is a specific structured protocol that begins with relaxation training, then cognitive restructuring, then exposure, and finally relapse prevention. The individualized version (CRCST-I) achieved significant full-remission improvements in the 2025 meta-analysis, while the group version did not.
Can DBT be used for IED?
DBT is used clinically for IED, particularly for patients with prominent emotion dysregulation. Its modules—mindfulness, distress tolerance, emotion regulation, and interpersonal effectiveness—map onto the deficits that maintain explosive outbursts. However, the direct evidence for DBT in IED is less developed than for CBT. A 2025 case evaluation found that a DBT-based protocol reduced anxiety but was “not completely effective in managing anger,” suggesting DBT may be best positioned as an adjunct or for patients with co-occurring emotion regulation difficulties.
Conclusion
Intermittent explosive disorder treatment sits at an uncomfortable intersection: the psychotherapy evidence is stronger than the pharmacological evidence, but neither is definitive, and the field lacks the large-scale, long-term trials that would establish a clear standard of care. What the 2025 meta-analysis and the 2026 adolescent RCT do establish is that individualized CBT and CRCST can produce full remission, that fluoxetine is useful for irritability but not remission, and that the pipeline of vasopressin antagonists may eventually give the field its first dedicated pharmacological treatment for pathological aggression.
For the practicing clinician, the implication is clear: do not treat IED as a medication problem with a therapy adjunct. Treat it as a psychological disorder with a biological substrate. Start with a structured, individualized psychotherapy protocol. Use medication to lower the intensity of symptoms enough for the patient to engage. Measure outcomes with a validated scale. Document the behavioral pattern and the functional impairment. And maintain the epistemic humility that a field without a definitive protocol demands.
The patient who has spent years believing they are simply “angry” or “out of control” deserves a clinician who understands that IED is a treatable condition with an evidence base—imperfect, but real.
References
If you’re ready to spend less time on documentation and more on therapy, get started with a free trial today
Not medical advice. For informational use only.
Outline
More articles
